

First patients in Hong Kong treated with Ortho-ATI™ therapy

- Orthocell expands presence in Asia
- First patients in Hong Kong undergo Ortho-ATI™ therapy
- Patients treated for degenerate tendon injuries

Perth, Australia; 9 February 2015: Regenerative medicine company Orthocell Limited has announced it has expanded its presence in Asia with the first patients treated with its world-leading tendon repair therapy in Hong Kong.

The two patients underwent the Ortho-ATI™ therapy last Friday, performed by respected Hong Kong Orthopaedic Surgeon Jason Brockwell from leading sports orthopaedic group Asia Medical Specialists.

The patients are receiving therapy to treat degenerate hamstring tendons that have been resistant to conservative treatment options such as corticosteroid injections and exercise regimes.

“This is an important step forward in the expansion of the Ortho-ATI™ treatment into Asia and comes on the back of solid clinical data that has been published and presented over the past year,” Orthocell Managing Director Paul Anderson said.

“There is great interest for a clinically effective treatment that has long term durability and cost effectiveness.”

Ortho-ATI™ involves taking tendon cells from a patient, expanding their number in an Australian Therapeutic Goods Authority-licensed laboratory and then injecting them into the patient’s damaged tendon to address the underlying pathology and regenerate the damaged tissue.

Asia is a key growth region for Orthocell and its innovative regenerative medicine therapies. The global regenerative medicine market has been forecast to reach \$US67.6 billion in 2020, from \$US16.4 billion in 2014, with the Asia-Pacific region expected to be the fastest growing region¹.

1. <http://www.prnewswire.co.uk/news-releases/regenerative-medicine-market-is-expected-to-reach-676-billion-global-by-2020-265200791.html>

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au

Investor relations

Rebecca Wilson
Buchan Consulting
P: 0417 382 391
E: rwilson@buchanwe.com.au

Media enquiries

Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.